Graves' ophthalmopathy

New England Journal of Medicine

Volumn 360, Issue 10, 2009, Pages 994-1001

  Bartalena, Luigi ^a   Tanda, Maria Laura ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; ANTITHYROID AGENT; BISPHOSPHONIC ACID DERIVATIVE; CYCLOSPORIN; GLUCOCORTICOID; IMMUNOGLOBULIN; LEVOTHYROXINE; LIOTHYRONINE; METHYLPREDNISOLONE; OCTREOTIDE; PLACEBO; PREDNISOLONE; PREDNISONE; PROTON PUMP INHIBITOR; RADIOACTIVE IODINE; RITUXIMAB; THIAMAZOLE; THYROTROPIN RECEPTOR ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ACUTE DISEASE; ADULT; ARTICLE; BLOOD PRESSURE; BONE ATROPHY; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DECOMPRESSION SURGERY; DIAGNOSTIC IMAGING; DIPLOPIA; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; ELECTROLYTE DISTURBANCE; ENDOCRINE OPHTHALMOPATHY; EPIPHORA; EUTHYROID SICK SYNDROME; EXOPHTHALMOS; EYE MOVEMENT; EYE PAIN; EYE SURGERY; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GAZE; HUMAN; HYPERGLYCEMIA; HYPERTHYROIDISM; HYPOTHYROIDISM; INFECTION; LIVER INJURY; LIVER TOXICITY; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; OPTIMAL DRUG DOSE; PERIORBITAL EDEMA; PHOTOPHOBIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THYROIDECTOMY; FEMALE; GRAVES DISEASE; MALE; PATHOPHYSIOLOGY; RADIOTHERAPY; REVIEW; SMOKING CESSATION;

ADULT; FEMALE; GLUCOCORTICOIDS; GRAVES DISEASE; GRAVES OPHTHALMOPATHY; HUMANS; IODINE RADIOISOTOPES; MALE; RADIOTHERAPY; SMOKING CESSATION;

EID: 61849108642     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp0806317     Document Type: Article

References (52)

1. Brent GA. Graves' disease. N Engl J Med 2008;358:2594-605.
2. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 2003;24:802-35.
3. Orgiazzi J. Pathogenesis. In: Wiersin-ga WM, Kahaly GJ, eds. Graves' orbitopa-thy: a multidisciplinary approach. Basel, Switzerland: Karger, 2007:41-56.
4. Burch HB, Wartofsky L. Graves' ophthalmopathy: current concepts regarding pathogenesis and treatment. Endocr Rev 1993;14:747-93.
5. Bahn RS. Pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 2003;88:1939-46.
6. Drexhage HA. Are there more than antibodies to the thyroid-stimulating hormone receptor that meet the eye in Graves' disease? Endocrinology 2006;147:9-12.
7. Bahn RS. Thyrotropin receptor expression in orbital adipose/connective tisues from patients with thyroid-associated ophthalmopathy. Thyroid 2002;12:193-5.
8. Weightman DR, Perros P, Sherif IH, Kendall-Taylor P. Autoantibodies to IGP-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity 1993;16:251-7.
9. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000; 21:168-99.
10. Bartalena L. Prevention. In: Wiersinga WM, Kahaly GJ, eds. Graves' orbitopathy: a multidisciplinary approach. Basel, Switzerland: Karger, 2007:229-36.
11. Bartley GB, Fatourechi V, Kadrmas EF, et al. Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol 1996;121:284-90.
12. Terwee CB, Gerding MN, Dekker FW, Prummel MF, Wiersinga WM. Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL. Br J Ophthalmol 1998;82:773-9.
13. Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995;42:45-50.
14. Bartalena L, Baldeschi L, Dickinson A, et al. Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol 2008;158:273-85.
15. Idem. Consensus statement of the European Group on Graves' Orbitopathy (EUGOGO) on management of Graves' orbitopathy. Thyroid 2008;18:333-46.
16. Mourits MP, Prummel MF, Wiersinga WM, Koornneef L. Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy. Clin Endocrinol (Oxf)1997;47:9-14. [Erratum, Clin Endocrinol (Oxf) 1997;47:632J
17. Terwee CB, Prummel MF, Gerding MN, Kahaly GJ, Dekker FW, Wiersinga WM. Measuring disease activity to predict therapeutic outcome in Graves' ophthalmopathy. Clin Endocrinol (Oxf) 2005;62: 145-55.
18. McKeag D, Lane C, Lazarus JH, et al. Clinical features of dysthyroid optic neuropathy: a European Group on Graves' Orbitopathy (EUGOGO) survey. Br J Ophthalmol 2007;91:455-8.
19. Wiersinga WM, Perros P, Kahaly GJ, et al. Clinical assessment of patients with Graves' orbitopathy: the European Group on Graves' Orbitopathy recommendations to generalists, specialists and clinical researchers. Eur J Endocrinol 2006;155: 387-9.
20. Bartalena L, Marcocci C, Chiovato L, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983;56:1139-44.
21. Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs. lifetime cigarette consumption. Clin Endocrinol (Oxf) 1996;45:477-81.
22. Prummel MF, Wiersinga WM, Mourits MP, Koornneef L, Berghout A, van der Gaag R. Amelioration of eye changes of Graves' ophthalmopathy by achieving eu-thyroidism. Acta Endocrinol (Copenh) 1989;121:Suppl 2:185-90.
23. Tallstedt L, Lundell G, Tørring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. N Engl J Med 1992;326:1733-8.
24. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998;338: 73-8.
25. Bartalena L, Marcocci C, Tanda ML, et al. Cigarette smoking and treatment outcomes in Graves ophthalmopathy. Ann Intern Med 1998;129:632-5.
26. Eckstein AJ, Plicht M, Lax H, et al. Thyrotropin receptor autoantibodies are independent risk factors for Graves' ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 2006;91:3464-70.
27. Tallstedt L, Lundell G, Blomgren H, Bring J. Does early administration of thyroxine reduce the development of Graves' ophthalmopathy after radioiodine treatment? Eur J Endocrinol 1994;130:494-7.
28. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A. Use of corticosteroids to prevent progression of Graves' ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989;321:1349-52.
29. Perros P, Kendall-Taylor P, Neoh C, Frewin S, Dickinson J. A prospective study of the effects of radioiodine therapy for hyperthyroidism in patients with minimally active Graves' ophthalmopathy. J Clin Endocrinol Metab 2005;90:5321-3.
30. Prummel MF, Terwee CB, Gerding MN, et al. A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves' ophthalmopathy. J Clin Endocrinol Metab 2004;89:15-20.
31. Wakelkamp IM, Baldeschi L, Saeed P, Mourits MP, Prummel MF, Wiersinga WM. Surgical or medical decompression as a first-line treatment in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf) 2005;63:323-8.
32. van Geest RJ, Sasim IV, Koppeschaar HPF, et al. Methylprednisolone pulse therapy for patients with moderately severe Graves' orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol 2008;158:229-37.
33. Perros P, Baldeschi L, Boboridis K, et al. A questionnaire survey on the management of Graves' orbitopathy in Europe. Eur J Endocrinol 2006;155:207-11.
34. Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001;86:3562-7.
35. Kahaly GJ, Pitz S, Hommel G, Dittmar M. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 2005;90:5234-40.
36. Weissel M, Hauff W. Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe eye disease. Thyroid 2000;10:521.
37. Marinó M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marcocci C. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 2004;14:403-6.
38. Le Moli R, Baldeschi L, Saeed P, Re-genburg N, Mourits MP, Wiersinga WM. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy. Thyroid 2007;17:357-62.
39. Mourits MP, van Kempen-Harteveld ML, Garcia MB, Koppeschaar HP, Tick L, Terwee CB. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet 2000;355:1505-9.
40. Bradley EA, Gower EW, Bradley DJ, et al. Orbital radiation for Graves ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2008;115:398-409.
41. Kahaly GJ, Rosier HP, Pitz S, Hommel G. Low- versus high-dose radiotherapy for Graves' ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab 2000;85:102-8.
42. Prummel MP, Mourits MP, Blank L, Berghout A, KoornneefL, Wiersinga WM. Randomised double-blind trial of prednisone vs. radiotherapy in Graves' ophthalmopathy. Lancet 1993;342:949-54.
43. Bartalena L, Lai A, Compri E, Mar-cocci C, Tanda ML. Novel immunomodu-lating agents for Graves orbitopathy. Oph-thal Plast Reconstr Surg 2008;24:251-6.
44. Prummel MP, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1989;321:1353-9.
45. El Passi D, Nielsen HC, Hasselbalch HC, Hegedüs L. Treatment-resistant severe, active Graves' ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 2006;16:709-10.
46. Salvi M, Vannucchi G, Campi I, et al. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007;156:33-40.
47. Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 2005;19: 1286-9.
48. Baldeschi L. Rehabilitative surgery. In: Wiersinga WM, Kahaly GJ, eds. Graves' orbitopathy: a multidisciplinary approach. Basel, Switzerland: Karger, 2007:160-62.
49. Idem. Orbital decompression. In: Wiersinga WM, Kahaly GJ, eds. Graves' orbitopathy: a multidisciplinary approach. Basel, Switzerland: Karger, 2007:163-75.
50. Baldeschi L, Wakelkamp IM, Linde-boom R, Prummel MP, Wiersinga WM. Early versus late orbital decompression in Graves' orbitopathy: a retrospective study in 125 patients. Ophthalmology 2006;113: 874-8.
51. Wiersinga WM. Preventing Graves' ophthalmopathy. N Engl J Med 1998; 338:121-2.
52. Menconi P, Marinò M, Pinchera A, et al. Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves' orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 2007;92:1653-8.